Compares the effects of long‐term treatment with (ultra‐)long‐acting insulin analogues to NPH insulin (neutral protamine Hagedorn) or another (ultra‐)long‐acting insulin analogue in people with type 1 diabetes mellitus.
This tool aims to assist decision makers when formulating evidence-based recommendations on national clinical guidelines and reimbursement decisions.
This report outlines European and United States guidelines on the interchangeability of biosimilars. It includes studies where people switched from an insulin reference product to a biosimilar and advice on the use of biosimilars in clinical practice.